Thus, although treatments designed to target VEGFR-1 specifically could be beneficial in the context of SARS-CoV-2 infection, further research is necessary to provide additional insights into the benefits of anti-VEGF therapy in SARS-CoV-2 infection, and especially in SARS-CoV-2/HIV co-infection. The gene discussed is VEGFA; the disease is coinfection.